TELA Bio, Inc.(TELA)Earnings, Financials & Key Ratios
TELA•NASDAQ
$0.99
$40M mkt cap·Price updated May 6, 2026
AboutTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Show more
- Revenue$69M+18.6%
- EBITDA-$33M+23.5%
- Net Income-$38M+18.9%
- EPS (Diluted)-1.33+34.8%
- Gross Margin67.08%-2.2%
- EBITDA Margin-47.77%+35.5%
- Operating Margin-49.23%+34.7%
- Net Margin-54.6%+31.6%
- ROE-159.87%+43.2%
- ROIC-151.56%+34.3%
- Debt/Equity1.51-33.2%
- Interest Coverage-6.45+23.6%
TELA Key Insights
TELA Bio, Inc. (TELA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 35.0%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 24.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
TELA Price & Volume
TELA Bio, Inc. (TELA) stock price & volume — 10-year historical chart
Loading chart...
TELA Growth Metrics
TELA Bio, Inc. (TELA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years35.02%
3 Years32.99%
TTM12.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.34%
Return on Capital
10 Years-80.07%
5 Years-56.03%
3 Years-66.55%
Last Year-51.37%
TELA Peer Comparison
TELA Bio, Inc. (TELA) competitors in Surgical tools, endoscopy, and robotics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTNT | 80.8M | 0.58 | -4.81 | 28.44% | 1.32% | 3.77% | 0.82 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 NVCR | 1.88B | 16.50 | -13.52 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSUR | 215.9M | 3.00 | -3.19 | -38.1% | -61.93% | -19.46% | 0.04 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 | |
 ANIK | 202.62M | 15.12 | -19.89 | -5.91% | -9.52% | -7.74% | 0.17 | |
 AHCO | 1.55B | 11.41 | -21.93 | -0.49% | -2.78% | -5.09% | 1.25 | |
 ANGO | 459.4M | 11.05 | -13.31 | -3.76% | -9.02% | -15.71% |
Compare TELA vs Peers
TELA Bio, Inc. (TELA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TELA Income Statement
TELA Bio, Inc. (TELA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.25M | 8.27M | 15.45M | 18.21M | 29.46M | 41.42M | 58.45M | 69.3M | 77.06M |
| Revenue Growth % | - | 94.91% | 86.68% | 17.91% | 61.77% | 40.58% | 41.13% | 18.56% | 12.24% |
| Cost of Goods Sold | 1.71M | 5.33M | 6.17M | 6.98M | 10.65M | 14.37M | 18.34M | 22.81M | 25.25M |
| COGS % of Revenue | 40.35% | 64.44% | 39.97% | 38.32% | 36.15% | 34.7% | 31.38% | 32.92% | - |
| Gross Profit | 2.53M▲ 0% | 2.94M▲ 16.2% | 9.27M▲ 215.2% | 11.23M▲ 21.2% | 18.81M▲ 67.5% | 27.04M▲ 43.8% | 40.11M▲ 48.3% | 46.49M▲ 15.9% | 51.81M▲ 0% |
| Gross Margin % | 59.65% | 35.56% | 60.03% | 61.68% | 63.85% | 65.3% | 68.62% | 67.08% | 67.23% |
| Gross Profit Growth % | - | 16.19% | 215.16% | 21.16% | 67.46% | 43.75% | 48.32% | 15.9% | - |
| Operating Expenses | 19.46M | 22.88M | 28.43M | 36.51M | 48.26M | 66.05M | 84.19M | 80.6M | 87.27M |
| OpEx % of Revenue | 458.33% | 276.58% | 184.09% | 200.46% | 163.81% | 159.47% | 144.03% | 116.31% | - |
| Selling, General & Admin | 13.67M | 18.55M | 24.28M | 32.25M | 41.52M | 57.11M | 74.57M | 79.37M | 78.15M |
| SG&A % of Revenue | 322.03% | 224.14% | 157.21% | 177.09% | 140.93% | 137.9% | 127.57% | 114.53% | - |
| Research & Development | 5.79M | 4.34M | 4.15M | 4.25M | 6.74M | 8.94M | 9.62M | 8.81M | 9.12M |
| R&D % of Revenue | 136.3% | 52.44% | 26.87% | 23.36% | 22.89% | 21.58% | 16.46% | 12.72% | - |
| Other Operating Expenses | 94K | 70K | 0 | 0 | 0 | 0 | 0 | -7.58M | 0 |
| Operating Income | -16.92M▲ 0% | -17.78M▼ 5.1% | -19.16M▼ 7.8% | -25.27M▼ 31.9% | -29.45M▼ 16.5% | -39.01M▼ 32.4% | -44.08M▼ 13.0% | -34.12M▲ 22.6% | -35.46M▲ 0% |
| Operating Margin % | -398.68% | -214.91% | -124.06% | -138.77% | -99.96% | -94.18% | -75.4% | -49.23% | -46.02% |
| Operating Income Growth % | - | -5.07% | -7.76% | -31.9% | -16.52% | -32.45% | -12.99% | 22.6% | - |
| EBITDA | -16.16M | -16.53M | -18.58M | -24.75M | -28.92M | -37.82M | -43.27M | -33.1M | -34.41M |
| EBITDA Margin % | -380.75% | -199.83% | -120.29% | -135.89% | -98.14% | -91.31% | -74.02% | -47.77% | -44.66% |
| EBITDA Growth % | - | -2.3% | -12.37% | -33.21% | -16.83% | -30.79% | -14.4% | 23.49% | 7.33% |
| D&A (Non-Cash Add-back) | 761K | 1.25M | 582K | 525K | 535K | 1.19M | 808K | 1.01M | 1.05M |
| EBIT | -16.78M | -19.29M | -18.82M | -25.23M | -29.68M | -40.24M | -41.44M | -32.7M | -34.17M |
| Net Interest Income | -4.56M | -1.8M | -3.61M | -3.56M | -3.6M | -4.05M | -5.22M | -5.29M | -4.89M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 4.56M | 1.8M | 3.61M | 3.56M | 3.6M | 4.05M | 5.22M | 5.29M | 4.89M |
| Other Income/Expense | -4.41M | -3.31M | -3.26M | -3.52M | -3.83M | -5.29M | -2.59M | -3.87M | -3.6M |
| Pretax Income | -21.33M▲ 0% | -21.09M▲ 1.1% | -22.43M▼ 6.3% | -28.79M▼ 28.4% | -33.28M▼ 15.6% | -44.3M▼ 33.1% | -46.66M▼ 5.3% | -37.98M▲ 18.6% | -39.06M▲ 0% |
| Pretax Margin % | -502.57% | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.81% | -50.69% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -144K | -59K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.38% | 0.15% |
| Net Income | -21.33M▲ 0% | -21.09M▲ 1.1% | -22.43M▼ 6.3% | -28.79M▼ 28.4% | -33.28M▼ 15.6% | -44.3M▼ 33.1% | -46.66M▼ 5.3% | -37.84M▲ 18.9% | -39M▲ 0% |
| Net Margin % | -502.57% | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.6% | -50.61% |
| Net Income Growth % | - | 1.13% | -6.32% | -28.4% | -15.57% | -33.12% | -5.35% | 18.91% | 6.08% |
| Net Income (Continuing) | -21.33M | -21.09M | -22.43M | -28.79M | -33.28M | -44.3M | -46.66M | -37.84M | -39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.29▲ 0% | -3.25▲ 1.2% | -2.26▲ 30.5% | -2.23▲ 1.3% | -2.30▼ 3.1% | -2.73▼ 18.7% | -2.04▲ 25.3% | -1.33▲ 34.8% | -0.86▲ 0% |
| EPS Growth % | - | 1.22% | 30.46% | 1.33% | -3.14% | -18.7% | 25.27% | 34.8% | 47.34% |
| EPS (Basic) | -3.29 | -3.25 | -2.26 | -2.23 | -2.30 | -2.73 | -2.04 | -1.33 | - |
| Diluted Shares Outstanding | 6.49M | 6.49M | 11.41M | 12.93M | 14.47M | 16.27M | 22.87M | 28.53M | 45.42M |
| Basic Shares Outstanding | 6.49M | 6.49M | 11.41M | 12.93M | 14.47M | 16.27M | 22.87M | 28.53M | 45.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
TELA Balance Sheet
TELA Bio, Inc. (TELA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 14.35M | 23.25M | 64.33M | 83.22M | 59.05M | 62.45M | 71.73M | 78.07M | 56.05M |
| Cash & Short-Term Investments | 11.35M | 17.28M | 54.59M | 74.39M | 43.93M | 42.02M | 46.73M | 52.67M | 29.71M |
| Cash Only | 11.35M | 17.28M | 45.3M | 74.39M | 43.93M | 42.02M | 46.73M | 52.67M | 29.71M |
| Short-Term Investments | 0 | 0 | 9.29M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 757K | 1.3M | 2.84M | 2.68M | 4.23M | 6.62M | 9.74M | 10.1M | 13.17M |
| Days Sales Outstanding | 65.09 | 57.26 | 67.02 | 53.77 | 52.45 | 58.35 | 60.8 | 53.19 | 56.21 |
| Inventory | 1.81M | 4.35M | 4.6M | 3.91M | 7.66M | 11.79M | 13.16M | 12.78M | 11.56M |
| Days Inventory Outstanding | 386.73 | 297.64 | 272.12 | 204.34 | 262.46 | 299.44 | 261.93 | 204.5 | 177.97 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 2.02M | 2.1M | 2.52M | 1.6M |
| Total Non-Current Assets | 1.19M | 3.97M | 3.59M | 3.23M | 3.49M | 5.41M | 6.32M | 9.25M | 5.54M |
| Property, Plant & Equipment | 1.16M | 758K | 677K | 626K | 1.19M | 2.91M | 3.94M | 4.08M | 3.77M |
| Fixed Asset Turnover | 3.66x | 10.92x | 22.82x | 29.09x | 24.84x | 14.24x | 14.84x | 16.99x | 19.87x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 3.21M | 2.91M | 2.61M | 2.3M | 2.5M | 2.12M | 1.74M | 1.45M |
| Long-Term Investments | 24K | 0 | 0 | 0 | 0 | 0 | 265K | 2.54M | 6.08M |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 15.53M▲ 0% | 27.23M▲ 75.3% | 67.92M▲ 149.5% | 86.46M▲ 27.3% | 62.54M▼ 27.7% | 67.86M▲ 8.5% | 78.05M▲ 15.0% | 87.33M▲ 11.9% | 61.59M▲ 0% |
| Asset Turnover | 0.27x | 0.30x | 0.23x | 0.21x | 0.47x | 0.61x | 0.75x | 0.79x | 1.05x |
| Asset Growth % | - | 75.3% | 149.47% | 27.29% | -27.66% | 8.49% | 15.02% | 11.89% | 47.77% |
| Total Current Liabilities | 6.15M | 9.56M | 6.71M | 6.61M | 10.57M | 12.4M | 16.97M | 15.6M | 16.98M |
| Accounts Payable | 1.51M | 3.42M | 3.17M | 652K | 2.41M | 1.53M | 1.67M | 2.15M | 2.37M |
| Days Payables Outstanding | 321.11 | 234.18 | 187.47 | 34.1 | 82.73 | 38.95 | 33.17 | 34.35 | 37.09 |
| Short-Term Debt | 905K | 0 | 0 | 0 | 0 | 340K | 565K | 545K | 521K |
| Deferred Revenue (Current) | 1.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.94M | 985K | 1.19M | 2.24M | 3.15M | 4.11M | 5.52M | 5.56M | 7.32M |
| Current Ratio | 2.33x | 2.43x | 9.58x | 12.60x | 5.58x | 5.03x | 4.23x | 5.01x | 5.01x |
| Quick Ratio | 2.04x | 1.98x | 8.90x | 12.01x | 4.86x | 4.08x | 3.45x | 4.19x | 4.19x |
| Cash Conversion Cycle | 130.72 | 120.72 | 151.67 | 224 | 232.18 | 318.83 | 289.56 | 223.33 | 197.09 |
| Total Non-Current Liabilities | 117.56M | 155.53M | 30.25M | 30.83M | 31.87M | 41.15M | 42.2M | 43.27M | 43.05M |
| Long-Term Debt | 3.61M | 29.73M | 30.24M | 30.83M | 31.49M | 39.92M | 40.52M | 41.12M | 41.49M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 1.2M | 1.69M | 1.39M | 1.39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 756K | 756K |
| Other Non-Current Liabilities | 113.94M | 125.8M | 4K | 0 | 380K | 31K | 0 | 0 | 4.12M |
| Total Liabilities | 123.7M | 165.09M | 36.96M | 37.43M | 42.45M | 53.55M | 59.17M | 58.87M | 60.03M |
| Total Debt | 4.51M | 29.73M | 30.24M | 30.83M | 31.49M | 41.46M | 42.77M | 43.06M | 42.02M |
| Net Debt | -6.83M | 12.46M | -15.06M | -43.57M | -12.44M | -563K | -3.96M | -9.61M | 12.3M |
| Debt / Equity | - | - | 0.98x | 0.63x | 1.57x | 2.90x | 2.26x | 1.51x | 1.51x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -1.22x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -0.36x |
| Interest Coverage | -3.71x | -9.87x | -5.31x | -7.09x | -8.19x | -9.63x | -8.44x | -6.45x | -6.99x |
| Total Equity | -108.17M▲ 0% | -137.86M▼ 27.4% | 30.96M▲ 122.5% | 49.03M▲ 58.3% | 20.1M▼ 59.0% | 14.3M▼ 28.8% | 18.88M▲ 32.0% | 28.46M▲ 50.7% | 1.56M▲ 0% |
| Equity Growth % | - | -27.45% | 122.46% | 58.34% | -59.01% | -28.82% | 31.99% | 50.72% | 421.54% |
| Book Value per Share | -16.67 | -21.25 | 2.71 | 3.79 | 1.39 | 0.88 | 0.83 | 1.00 | 0.03 |
| Total Shareholders' Equity | -108.17M | -137.86M | 30.96M | 49.03M | 20.1M | 14.3M | 18.88M | 28.46M | 1.56M |
| Common Stock | 7K | 0 | 11K | 14K | 15K | 19K | 24K | 39K | 40K |
| Retained Earnings | -108.17M | -137.86M | -167.86M | -196.65M | -229.93M | -274.23M | -320.89M | -358.73M | -388.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.79M | -3.24M | -19K | -71K | -52K | 150K | 91K | 90K | 91K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TELA Cash Flow Statement
TELA Bio, Inc. (TELA) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -16.37M | -19.92M | -25.52M | -24.46M | -30.43M | -40.75M | -40.86M | -41.59M | -41.59M |
| Operating CF Margin % | -385.58% | -240.8% | -165.24% | -134.28% | -103.29% | -98.38% | -69.9% | -60.02% | - |
| Operating CF Growth % | - | -21.73% | -28.1% | 4.18% | -24.44% | -33.9% | -0.27% | -1.81% | 126.68% |
| Net Income | -21.33M | -21.09M | -22.43M | -28.79M | -33.28M | -44.3M | -46.66M | -37.84M | -39M |
| Depreciation & Amortization | 761K | 1.25M | 582K | 525K | 535K | 1.19M | 808K | 1.01M | 1.05M |
| Stock-Based Compensation | 197K | 216K | 457K | 2.06M | 3.66M | 3.99M | 5.03M | 4.36M | 3.12M |
| Deferred Taxes | -40K | 1.22M | 5K | 0 | 14K | 0 | 0 | -144K | 85K |
| Other Non-Cash Items | 3.97M | 2.94M | 2.09M | 1.84M | 2.1M | 4.13M | 1.64M | -4.12M | 4.44M |
| Working Capital Changes | 75K | -4.46M | -6.24M | -86K | -3.47M | -5.76M | -1.67M | -4.87M | -574K |
| Change in Receivables | -578K | -541K | -1.53M | 149K | -1.55M | -2.42M | -3.06M | -762K | -59K |
| Change in Inventory | -127K | -4.76M | -1.84M | -620K | -5.19M | -6.07M | -2.72M | -2.97M | -844K |
| Change in Payables | -748K | 1.91M | -773K | -2M | 1.6M | -884K | 11K | 482K | 50K |
| Cash from Investing | -101K | -1.56M | -11.98M | 9.12M | -627K | -1.87M | -599K | 4.45M | 464K |
| Capital Expenditures | -114K | -1.56M | -2.7M | -167K | -627K | -872K | -611K | 0 | -621K |
| CapEx % of Revenue | 2.69% | 18.88% | 17.46% | 0.92% | 2.13% | 2.11% | 1.05% | 1.43% | - |
| Acquisitions | 13K | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 523K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 13K | 4K | 0 | 0 | 0 | -1M | 12K | 4.45M | 562K |
| Cash from Financing | 26.34M | 27.41M | 65.53M | 44.41M | 585K | 40.85M | 46.27M | 43.06M | 42.81M |
| Debt Issued (Net) | 12.2M | 25M | 0 | 0 | 0 | 10M | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 3.98M | 65.52M | 44.72M | 585K | 34.4M | 46.34M | 42.92M | 43.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14K |
| Other Financing | 14.14M | -1.56M | 14K | -313K | 0 | -3.55M | -74K | 138K | -209K |
| Net Change in Cash | 9.87M▲ 0% | 5.93M▼ 39.9% | 28.02M▲ 372.4% | 29.09M▲ 3.8% | -30.46M▼ 204.7% | -1.91M▲ 93.7% | 4.97M▲ 360.2% | 5.94M▲ 19.4% | 12.41M▲ 0% |
| Free Cash Flow | -16.48M▲ 0% | -21.49M▼ 30.4% | -28.22M▼ 31.3% | -24.62M▲ 12.7% | -31.06M▼ 26.1% | -42.62M▼ 37.2% | -41.47M▲ 2.7% | -42.58M▼ 2.7% | -31.5M▲ 0% |
| FCF Margin % | -388.27% | -259.68% | -182.7% | -135.19% | -105.42% | -102.9% | -70.94% | -61.45% | -40.88% |
| FCF Growth % | - | -30.36% | -31.34% | 12.75% | -26.14% | -37.22% | 2.7% | -2.69% | 31.59% |
| FCF per Share | -2.54 | -3.31 | -2.47 | -1.90 | -2.15 | -2.62 | -1.81 | -1.49 | -1.49 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.94x | 1.14x | 0.85x | 0.91x | 0.92x | 0.88x | 1.10x | 0.81x |
| Interest Paid | 0 | 0 | 0 | 2.98M | 0 | 3.39M | 4.62M | 0 | 1.89M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TELA Key Ratios
TELA Bio, Inc. (TELA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -72.43% | -72% | -96.28% | -257.51% | -281.23% | -159.87% | -272.13% |
| Return on Invested Capital (ROIC) | - | - | -177.48% | -336.79% | -273.41% | -230.69% | -151.56% | -151.56% |
| Gross Margin | 35.56% | 60.03% | 61.68% | 63.85% | 65.3% | 68.62% | 67.08% | 67.23% |
| Net Margin | -254.92% | -145.18% | -158.1% | -112.94% | -106.95% | -79.83% | -54.6% | -50.61% |
| Debt / Equity | - | 0.98x | 0.63x | 1.57x | 2.90x | 2.26x | 1.51x | 1.51x |
| Interest Coverage | -9.87x | -5.31x | -7.09x | -8.19x | -9.63x | -8.44x | -6.45x | -6.99x |
| FCF Conversion | 0.94x | 1.14x | 0.85x | 0.91x | 0.92x | 0.88x | 1.10x | 0.81x |
| Revenue Growth | 94.91% | 86.68% | 17.91% | 61.77% | 40.58% | 41.13% | 18.56% | 12.24% |
TELA Frequently Asked Questions
TELA Bio, Inc. (TELA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
TELA Bio, Inc. (TELA) reported $77.1M in revenue for fiscal year 2024. This represents a 1715% increase from $4.2M in 2017.
TELA Bio, Inc. (TELA) grew revenue by 18.6% over the past year. This is strong growth.
TELA Bio, Inc. (TELA) reported a net loss of $39.0M for fiscal year 2024.
Dividend & Returns
TELA Bio, Inc. (TELA) has a return on equity (ROE) of -159.9%. Negative ROE indicates the company is unprofitable.
TELA Bio, Inc. (TELA) had negative free cash flow of $31.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More TELA
TELA Bio, Inc. (TELA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates